Form 4: Moderna Director Noubar Afeyan Sells Shares Worth Millions

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on June 5, 2024, under a pre-arranged trading plan.

Summary

• On June 5, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• A total of 14,000 shares were sold in multiple transactions at varying prices.
• The prices ranged from $145.40 to $155.27 per share.
• Following the reported transactions, Afeyan directly owns 1,946,931 shares of Moderna common stock.
• Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sale was pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a negative outlook, but it's a significant transaction that warrants attention.

Risks

• The sale of shares by a director could be perceived negatively by investors, although it was conducted under a pre-arranged trading plan.

Industry Context

Insider trading activity is always closely watched in the biotech industry, especially for companies like Moderna that have experienced significant volatility due to the COVID-19 pandemic and vaccine development.

Comparison to Industry Standards

• Monitoring insider sales is a common practice to gauge executive sentiment; however, sales under 10b5-1 plans are less informative since they are pre-scheduled.
• Comparing Afeyan's transactions to other directors' sales in peer companies like BioNTech or Pfizer could provide additional context, but this data isn't provided in the document.

Stakeholder Impact

• The stock sale could cause short-term fluctuations in the stock price, impacting shareholders.
• The sale itself doesn't directly impact employees, customers, suppliers, or creditors.

Key Dates